Avtor/Urednik		Kanič, Vojko
Naslov		Klopidogrel in koronarna bolezen
Prevedeni naslov		Clopidogrel and coronary heart disease
Tip		članek
Vir		In: Hojs R, Krajnc I, Pahor A, et al, editors. Zbornik predavanj in praktikum 15. srečanje internistov in zdravnikov splošne medicine Iz prakse za prakso z mednarodno udeležbo; 2004 maj 7-8; Maribor. Maribor: Splošna bolnišnica Maribor,
Leto izdaje		2004
Obseg		str. 259-66
Jezik		slo
Abstrakt		The inhibition of platelet activity decreases mortality in cardiovascular patients. The ADP antagonist clopidogrel effectively inhibits platelet activity. All patients with acute coronary syndrome (ACS) should receive clopidogrel for a minimum of nine months. If PTCA is performed, clopidogrel and aspirin should be recommended for at least one year.
Deskriptorji		CORONARY DISEASE PLATELET AGGREGATION INHIBITORS